The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Pre-transplant MRD status by NGS as a prognostic tool for AML and MDS
In this interview, Saar Gill, MD, PhD, from the University of Pennsylvania, Philadelphia, PA., discusses a retrospective review looking at the outcomes for patients with either acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) receiving allogeneic stem cell transplants (allo-SCT) based on pre-transplant measurable residual disease (MRD) status determined by next-generation sequencing (NGS). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Dr Gill reveals similar outcomes are observed regardless of molecular MRD findings for the patients, meaning a patient does not need an MRD negative complete response prior to transplant to benefit from this treatment.
